Bayer (BAYRY) told media outlets in a statement, “Bayer is on track with its plan to exit the analyst health business. Following a strategic review of exit options, the primary focus is on a sale. However, Bayer also continues to consider all value-maximizing options. We will not be making any further comments at this stage.” The statement follows a report from Reuters that Bayer is seeking to merge its animal health unit with Elanco Animal Health (ELAN). Shares of Elanco are off their highs but remain up 26c to $33.62 in midday trading.